Trials / Terminated
TerminatedNCT00944372
Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors
An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate the effect of age (geriatric) and renal function on the safety, efficacy and pharmacokinetics of OctreoScan at the recommended clinical dose in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indium In-111 pentetreotide | Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2009-07-23
- Last updated
- 2016-09-09
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00944372. Inclusion in this directory is not an endorsement.